Evidence map›Paper›PMID 37545524›Full record

Trial reportFrontiers in immunology2023

Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model.

Salma Assil, Thomas P Buters, Pieter W Hameeteman, Charlie Hallard, Nicoline Treijtel, Tessa Niemeyer-Van der Kolk, Marieke L de Kam, Edwin F I I I Florencia, Errol P Prens, Martijn B A van Doorn and 4 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Salma AssilCentre for Human Drug Research, Leiden, Netherlands.
Thomas P ButersCentre for Human Drug Research, Leiden, Netherlands.
Pieter W HameetemanCentre for Human Drug Research, Leiden, Netherlands.
Charlie HallardCentre for Human Drug Research, Leiden, Netherlands.
Nicoline TreijtelCentre for Human Drug Research, Leiden, Netherlands.
Tessa Niemeyer-Van der KolkCentre for Human Drug Research, Leiden, Netherlands.
Marieke L de KamCentre for Human Drug Research, Leiden, Netherlands.
Edwin F I I I FlorenciaDepartment of Dermatology Erasmus Medical Centre, Rotterdam, Netherlands.
Errol P PrensDepartment of Dermatology Erasmus Medical Centre, Rotterdam, Netherlands.
Martijn B A van DoornDepartment of Dermatology Erasmus Medical Centre, Rotterdam, Netherlands.
Robert RissmannCentre for Human Drug Research, Leiden, Netherlands.
Naomi B KlarenbeekCentre for Human Drug Research, Leiden, Netherlands.
Manon A A JansenCentre for Human Drug Research, Leiden, Netherlands.
Matthijs MoerlandCentre for Human Drug Research, Leiden, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imiquimod (IMQ) is a topical agent that induces local inflammation

Indexed as

BlisterDermatitisAnti-Inflammatory AgentsHealthy VolunteersHumansImiquimodInflammationPrednisoloneAnti-Inflammatory AgentsImiquimodPrednisolonecorticosteroidshealthy volunteerimiquimodinflammatory modelTLR7

Identifiers

PMID37545524
PMCPMC10400434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.